ESGCT Research Articles

European Society of Gene and Cell Therapy (ESGCT) - 28th Annual Meeting. Virtual - October 19-22, 2021

European Society of Gene and Cell Therapy (ESGCT) - 28th Annual Meeting. Virtual - October 19-22, 2021

Keys to Delivery: An Interview with Hildegard Büning

Editor's note: Hildegard Büning is one of the leading gene therapy researchers in Europe. She has been a key figure in the field of adeno-associated virus research and capsid engineering for some two decades, and is currently deputy director of the Institute of Experimental Hematology at Hannover Medical School in Germany. She has also had a long-standing interest in serving the broader gene therapy community, and is currently president of the European Society of Gene and Cell Therapy (ESGCT). In this exclusive interview, we asked Professor Büning to share some career highlights and motivations, including her latest plans for ESGCT.

Update on the Sleeping Beauty transposon system: current state-of-the-art & remaining challenges

Zoltán Ivics received his PhD in molecular biology in 1994. After postoctoral studies at the University of Minnesota in the USA and the Netherlands Cancer Institute, he was appointed as a research group leader at the Max Delbrück Center for Molecular Medicine in Berlin, Germany. He was appointed as Head of Division at the Paul Ehrlich Institute in Langen, Germany, in 2011. Prof. Ivics’ major scientific achievement is the molecular reconstruction of the Sleeping Beauty transposon and development of technologies based on Sleeping Beauty gene transfer for a wide array of applications involving genetic engineering of cells. Prof. Ivics has published >130 papers in peer reviewed journals, with a total Impact Factor of >800 and >7000 citations (h-index: 44), and is co-inventor on 12 patents. Since 2000 his research efforts were supported by >20 research grants from the German Research Foundation, the German Ministry of Education and Research, the European Commission, and the Volkswagen Foundation. He received recognition of the ‘Molecule of the Year’ in 2009 for developing a hyperactive Sleeping Beauty transposase that opened the door for clinical applications. He is a current member of the Board of the European Society of Gene and Cell Therapy (ESGCT), member of the Board of the German Society of Gene Therapy and member of the committee for ‘Clinical trials and regulatory affairs’ of the German Stem Cell Network. Prof. Ivics organized several international conferences, including the Annual Congress of the ESGCT in Berlin in 2017. He is an Elected Member of the Academia Europaea since 2018.

Call for Submissions for The 2020 European Society of Gene and Cell Therapy (ESGCT) Special Issue: Gene and Cell Therapy for Inherited and Acquired Immune Deficiency.

Call for Submissions for The 2020 European Society of Gene and Cell Therapy (ESGCT) Special Issue: Gene and Cell Therapy for Inherited and Acquired Immune Deficiency.

Call for Submissions for The 2020 European Society of Gene and Cell Therapy (ESGCT) Special Issue: Gene and Cell Therapy for Inherited and Acquired Immune Deficiency.

Call for Submissions for The 2020 European Society of Gene and Cell Therapy (ESGCT) Special Issue: Gene and Cell Therapy for Inherited and Acquired Immune Deficiency.

Call for Submissions for The 2020 European Society of Gene and Cell Therapy (ESGCT) Special Issue: Gene and Cell Therapy for Inherited and Acquired Immune Deficiency.

Call for Submissions for The 2020 European Society of Gene and Cell Therapy (ESGCT) Special Issue: Gene and Cell Therapy for Inherited and Acquired Immune Deficiency.

Call for Submissions for The 2020 European Society of Gene and Cell Therapy (ESGCT) Special Issue: Gene and Cell Therapy for Inherited and Acquired Immune Deficiency.

Call for Submissions for The 2020 European Society of Gene and Cell Therapy (ESGCT) Special Issue: Gene and Cell Therapy for Inherited and Acquired Immune Deficiency.

European Society of Gene and Cell Therapy (ESGCT) - 27th Annual Congress. Barcelona, Spain - October 22-25, 2019

European Society of Gene and Cell Therapy (ESGCT) - 27th Annual Congress. Barcelona, Spain - October 22-25, 2019

European Society of Gene and Cell Therapy (ESGCT) at 25: A Gene Therapy Community at Its Prime and on the Move

European Society of Gene and Cell Therapy (ESGCT) at 25: A Gene Therapy Community at Its Prime and on the Move

The next generation of stem cell therapy: “From cartilage explants to arthritic patients”

The next generation of stem cell therapy: “From cartilage explants to arthritic patients”

ESGCT and FSGT Collaborative Congress Helsinki, Finland September 17-20, 2015 Abstracts.

ESGCT and FSGT Collaborative Congress Helsinki, Finland September 17-20, 2015 Abstracts.

The Need for Increased Clarity and Transparency in the Regulatory Pathway for Gene Medicines in the European Union

At the October 2011 meeting of the European Society of Gene and Cell Therapy (ESGCT) in Brighton, UK, the society hosted an excellent symposium in collaboration with the Committee on Advanced Therapies (CAT) of the European Medicines Agency (EMA), with a view to discussing problems and road blocks that biotech companies face when trying to bring Advanced Therapy Medicinal Products (ATMP) through the regulatory process. Overshadowing the symposium was the recent decision by the EMA to reject approval of Amsterdam Molecular Therapeutic’s Glybera (alipogene tiparvovec) despite an approval recommendation by the CAT. Thus, despite the considerable professional expertise of the CAT and their attempts to guide sponsors through the regulatory pathway in the EU, the process remains fraught with uncertainty and it was the clear consensus of the symposium that additional clarification of the authority of the CAT in the decision-making process was urgently needed.

XVIII Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)October 22–25, 2010Milan, Italy

XVIII Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)October 22–25, 2010Milan, Italy

ESGCT, DGGT, GSZ, and ISCT 2009 Abstract Author Index

Human Gene TherapyVol. 20, No. 11 ESGCT, DGGT, GSZ, and ISCT 2009 Abstract Author IndexPublished Online:4 Nov 2009https://doi.org/10.1089/hum.2009.0927AboutSectionsView articleView Full TextPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 20Issue 11Nov 2009 InformationCopyright 2009, Mary Ann Liebert, Inc.To cite this article:ESGCT, DGGT, GSZ, and ISCT 2009 Abstract Author Index.Human Gene Therapy.Nov 2009.1546-1558.http://doi.org/10.1089/hum.2009.0927Published in Volume: 20 Issue 11: November 4, 2009PDF download

ESGCT 2008 Invited Presentations

ESGCT 2008 Invited Presentations

The Twelfth Annual Meeting of the European Society of Gene Therapy

The Twelfth Annual Meeting of the European Society of Gene Therapy

The Journal of Gene Medicine 2002 Young Investigator Award. European Society of Gene Therapy.

The Journal of Gene MedicineVolume 5, Issue 1 p. 85-86 Young Investigator Award The Journal of Gene Medicine 2002 Young Investigator Award European Society of Gene Therapy Dr Niels-Bjarne Woods, Corresponding Author Dr Niels-Bjarne Woods Department of Molecular Medicine and Gene Therapy (Professor Stefan Karlsson), Lund University, SwedenDepartment of Molecular Medicine and Gene Therapy (Professor Stefan Karlsson), Lund University, SwedenSearch for more papers by this author Dr Niels-Bjarne Woods, Corresponding Author Dr Niels-Bjarne Woods Department of Molecular Medicine and Gene Therapy (Professor Stefan Karlsson), Lund University, SwedenDepartment of Molecular Medicine and Gene Therapy (Professor Stefan Karlsson), Lund University, SwedenSearch for more papers by this author First published: 06 January 2003 https://doi.org/10.1002/jgm.365Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume5, Issue1January 2003Pages 85-86 RelatedInformation

French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy.

The Journal of Gene MedicineVolume 5, Issue 1 p. 82-84 Society Communication French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID) Position statement from the European Society of Gene Therapy (ESGT) First published: 06 January 2003 https://doi.org/10.1002/jgm.364Citations: 20Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Citing Literature Volume5, Issue1January 2003Pages 82-84 RelatedInformation

Immunomodulatory gene therapy for haematological malignancies.

Immunomodulatory gene therapy for haematological malignancies.

Eighth Meeting of the European Society of Gene Therapy (ESGT), 7–10 October 2000, Stockholm, Sweden

Eighth Meeting of the European Society of Gene Therapy (ESGT), 7–10 October 2000, Stockholm, Sweden